Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Loquai, Carmen
EBIN, NCT03235245 / 2017-002887-42: Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib	Active, not recruiting	2	271	Europe	Nivolumab + Ipilimumab, Encorafenib + Binimetinib	European Organisation for Research and Treatment of Cancer - EORTC	Unresectable Stage III Melanoma, Stage IV Melanoma	10/23	01/27
Grabbe, Stephan
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Active, not recruiting	3	407	Europe, US, RoW	IO102-IO103, Pembrolizumab	IO Biotech, Syneos Health, Merck Sharp & Dohme LLC	Metastatic Melanoma, Unresectable Melanoma	07/25	09/27
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Active, not recruiting	2	220	Europe, US, RoW	Botensilimab, AGEN1181, Balstilimab, AGEN2034	Agenus Inc.	Advanced Melanoma	05/28	05/28
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().	Completed	1/2	29	Europe, US	ANV419, Pembrolizumab, Ipilimumab	Anaveon AG, Anaveon AG	Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma	08/24	08/24